PMID- 21504383
OWN - NLM
STAT- MEDLINE
DCOM- 20111024
LR  - 20200502
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 6
DP  - 2011 Jun
TI  - Does pretreatment fluorescence in situ hybridization for BCR-ABL predict 
      imatinib-associated hematologic toxicity in chronic myeloid leukemia?
PG  - 1010-6
LID - 10.3109/10428194.2011.559670 [doi]
AB  - Imatinib (IM)-associated myelosuppression is rare in gastrointestinal stromal 
      cell tumors (<10%) but common in chronic myeloid leukemia (CML). Selective 
      inhibition of predominantly Philadelphia chromosome (Ph+) driven hematopoiesis 
      may explain myelosuppression in CML. In the absence of clinical methods to 
      quantitate the Ph+/Ph- progenitor ratio, we hypothesized that the pre-IM 
      percentage of BCR-ABL+ cells measured by fluorescence in situ hybridization 
      (FISH) predicts for myelosuppression. FISH analyses performed within 30 days 
      pre-IM 400 mg/day were analyzed in 89 patients with chronic phase CML at three 
      institutions. Patients who developed grade >/=3 cytopenias had a higher percentage 
      of positive FISH (90% vs. 83%; p = 0.02). Cytopenias lasted a median of 16 days, 
      and all patients but one continued IM, achieved complete hematologic and 
      cytogenetic remissions, and did not experience progression, with a follow-up of 
      61 months. In conclusion, IM-associated cytopenias are associated with a high 
      pre-IM FISH, are reversible, and do not adversely affect outcomes.
FAU - Lima, Lisa M
AU  - Lima LM
AD  - Department of Hematology and Medical Oncology, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - Sampat, Keeran
AU  - Sampat K
FAU - Assouline, Sarit
AU  - Assouline S
FAU - Saxe, Debra
AU  - Saxe D
FAU - Nault, Sharron
AU  - Nault S
FAU - Tighiouart, Mourad
AU  - Tighiouart M
FAU - McLemore, Morgan
AU  - McLemore M
FAU - Arellano, Martha
AU  - Arellano M
FAU - Winton, Elliott
AU  - Winton E
FAU - Bernal-Mizrachi, Leon
AU  - Bernal-Mizrachi L
FAU - Cortes, Jorge
AU  - Cortes J
FAU - Khoury, Hanna Jean
AU  - Khoury HJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20110420
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Benzamides)
RN  - 0 (Oncogene Proteins v-abl)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-bcr)
SB  - IM
CIN - Leuk Lymphoma. 2011 Jun;52(6):943. PMID: 21599589
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzamides
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Fusion Proteins, bcr-abl/*genetics
MH  - Hematologic Diseases/*chemically induced
MH  - Humans
MH  - Imatinib Mesylate
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins v-abl/genetics
MH  - Piperazines/*adverse effects/therapeutic use
MH  - Prognosis
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Proto-Oncogene Proteins c-bcr/genetics
MH  - Pyrimidines/*adverse effects/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/04/21 06:00
MHDA- 2011/10/25 06:00
CRDT- 2011/04/21 06:00
PHST- 2011/04/21 06:00 [entrez]
PHST- 2011/04/21 06:00 [pubmed]
PHST- 2011/10/25 06:00 [medline]
AID - 10.3109/10428194.2011.559670 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Jun;52(6):1010-6. doi: 10.3109/10428194.2011.559670. Epub 
      2011 Apr 20.